Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer

Thyroid

Volumn 19, Issue 9, 2009, Pages 953-956

  Kebebew, Electron ^a,b,d   Lindsay, Sheila ^a   Clark, Orlo H ^a,b   Woeber, Kenneth A ^c   Hawkins, Randall ^d   Greenspan, Francis S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Medicine ^*

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; ROSIGLITAZONE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMAGING; LUNG METASTASIS; MALE; NECK TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THYROID CANCER; THYROID FOLLICLE CELL; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS;

EID: 70349160428     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0371     Document Type: Article

References (23)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83:2638-2648.
2. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium=iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875.
3. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)=I( ) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-3435.
4. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M, Boccuzzi G 2006 Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxo-rubicin in anaplastic thyroid cancer cells. J Endocrinol 191:465-472.
5. Koeffler HP 2003 Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9:1-9.
6. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A 2002 PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-932.
7. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231.
8. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y 2004 Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 4:465-477.
9. Venkataraman GM, Yatin M, Marcinek R, Ain KB 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na +/=I-symporter gene methylation status. J Clin Endocrinol Metab 84:2449-2457.
10. Frohlich E, Machicao F, Wahl R 2005 Action of thiazolidi-nediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12:291-303.
11. Philips JC, Petite C, Willi JP, Buchegger F, Meier CA 2004 Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun 25:1183-1186.
12. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SKG, Eberhardt NL, McIver B 2005 PPARgamma staining as a surrogate for PAX8=PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopatho-logical diagnostic value. J Clin Endocrinol Metab 90:463-468.
13. Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG, Leite V 2004 Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8= PPARgamma-negative thyroid tumours. Br J Cancer 91:732-738.
14. Karger S, Berger K, Eszlinger M, Tannapfel A, Dralle H, Paschke R, Fuhrer D 2005 Evaluation of peroxisome pro-liferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid 15:997-1003.
15. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spie-gelman BM, Fletcher JA 2000 PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289:1357-1360.
16. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY 2006 PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 25: 2736-2747.
17. Baetz T, Eisenhauer E, Siu L, MacLean M, Doppler K, Walsh W, Fisher B, Khan AZ, de Alwis DP, Weitzman A, Brail LH, Moore M 2007 A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tu-mours. Invest New Drugs 25:217-225.
18. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW 2004 Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and=or radiation therapy. Cancer 101:1569-1574.
19. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A 2003 A phase II trial with rosigli-tazone in liposarcoma patients. Br J Cancer 89:1409-1412.
20. National Cancer Institute 2006 Clinical trials. http://clinicaltrials. gov=ct2=results?term=thyroidcancer. Accessed April 2009.
21. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita E 2006 A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140:960-966; discussion 966-967.
22. Therasse P, Eisenhauer EA, and Buyse M 2006 Update in methodology and conduct of cancer clinical trials. Eur J Cancer 42:1322-1330.
23. Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P 2008 Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of perox-isome proliferator-activated receptor-gamma. Thyroid 18:697-704.